Cannabigerol — The Sunlight Experiment

Pharmacology & Research

Cannabigerol is the “mother cannabinoid”: its acidic form, cannabigerolic acid, is the central building block the plant converts into the acidic forms of THC, CBD and CBC, so mature high-THC or high-CBD plants usually retain little CBG. It’s non-intoxicating, and its pharmacology is its own — a highly potent α2-adrenoceptor agonist and a 5-HT1A antagonist ^{1Reference 1Cascio MG et al. · 2010In vitroEvidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitroView study →}, plus activity at the TRP ion channels (TRPA1 agonist, TRPM8 antagonist, TRPV1 agonist) ^{3Reference 3De Petrocellis L et al. · 2011In vitroEffects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes — in vitroView study →}. That profile has driven interest in anti-inflammatory and appetite effects, but the evidence is entirely preclinical — no human trials yet.

What the evidence supports

Preclinical signals: reduces colonic inflammation in a mouse colitis model ^{2Reference 2Borrelli F et al. · 2013AnimalBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis modelView study →}; stimulates appetite in rats without THC-like side effects ^{4Reference 4Brierley DI et al. · 2016AnimalCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding modelView study →}.
Distinctive mechanism: an unusually potent α2-adrenoceptor agonist and 5-HT1A antagonist ^{1Reference 1Cascio MG et al. · 2010In vitroEvidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitroView study →} with a defined TRP-channel profile ^{3Reference 3De Petrocellis L et al. · 2011In vitroEffects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes — in vitroView study →}.
The honest headline: there is no human efficacy data for CBG — its reputation runs well ahead of the evidence.

0. Evidence by application

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. For CBG every entry is animal/in-vitro, so scores stay low by design. Each application links to its write-up.

Application	Support	Rests on
Anti-inflammatory (gut)	████░░░░░░ 42%	Mouse colitis model; anti-inflammatory + antioxidant ^{2Reference 2Borrelli F et al. · 2013AnimalBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis modelView study →}
Appetite stimulation	████░░░░░░ 40%	Rat feeding study; clean appetite signal without THC side effects ^{4Reference 4Brierley DI et al. · 2016AnimalCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding modelView study →}

1. Anti-inflammatory (gut)

In a chemically induced (DNBS) colitis model in mice, CBG reduced colon inflammation, nitric-oxide production and oxidative stress, and normalised markers of intestinal damage ^{2Reference 2Borrelli F et al. · 2013AnimalBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis modelView study →} — consistent with the broader interest in non-intoxicating cannabinoids for inflammatory bowel conditions.

Gap: a single animal model; no human data, and the effective route/dose in people is unknown ^{2Reference 2Borrelli F et al. · 2013AnimalBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis modelView study →}.

2. Appetite stimulation

In pre-satiated rats, CBG dose-dependently increased food intake — more meals and a shorter latency to feed — without the neuromotor side effects THC produces, making it a notably “clean” appetite stimulant in that model ^{4Reference 4Brierley DI et al. · 2016AnimalCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding modelView study →}.

Gap: rodent feeding behaviour only; whether CBG stimulates appetite in humans, and at what dose, is untested ^{4Reference 4Brierley DI et al. · 2016AnimalCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding modelView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
α2-adrenoceptor agonism (potent)	adrenergic modulation, analgesia	broad
5-HT1A antagonism	mood/appetite signalling (opposite direction to CBD)	appetite, mood
TRPA1 agonism / TRPM8 antagonism; TRPV1 agonism	anti-inflammatory, sensory modulation	inflammation
CB1/CB2 partial agonism (weak)	mild endocannabinoid tone	broad

Pharmacokinetics

Human pharmacokinetic data for CBG are sparse. As a lipophilic cannabinoid it is expected to share cannabinoids’ general pattern — poor and variable oral absorption with extensive first-pass metabolism — but this has not been well characterised in people, and any figure would be an extrapolation rather than a measurement.

Clinical trials

CBG has no completed efficacy trials; interest is commercial and preclinical, with early human safety/pharmacokinetic work only beginning.

Completed	Planned	Terminated	Preclinical
— (efficacy)	Early-phase	—	Growing

Last checked: July 2026.

Toxicity & Safety

CBG is non-intoxicating and appears well tolerated in the preclinical work done so far, but it has been studied far less in humans than THC or CBD, so its safety profile and drug-interaction potential are not established. Given its α2-adrenergic activity, theoretical interactions with blood-pressure or sedative medications are plausible but untested. As with all cannabis-derived products, commercial CBG preparations vary in purity and labelled content.

Pregnancy & lactation

Avoid (precautionary). There are no safety data for CBG in pregnancy or breastfeeding, and as a cannabis constituent it is prudent to avoid — absence of studies is not evidence of safety.

Dosage

There is no established human dose for CBG. The effects described above come from animal and in-vitro studies whose doses (e.g. mg/kg in rodents) do not convert to human use. Commercial products are sold without a research-backed dosing basis. Treat any figure as unverified — this is not a recommendation.

References

Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitro. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/20002104/
Borrelli F, Fasolino I, Romano B, et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis model. Biochemical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/23415610/
De Petrocellis L, Ligresti A, Moriello AS, et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes — in vitro. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/21175579/
Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding model. Psychopharmacology (Berl). https://pubmed.ncbi.nlm.nih.gov/27503475/